Abstract
Background: Proprotein convertase subtilisin/Kexin type 9 (PCSK-9) inhibitors induced liver dysfunction in patients with or without previous liver injury, and this is not well discussed in the previous literature. Methods: A total sample of 202 patients were retrospectively reviewed at the University of Missouri, Kansas City, from the year 2015 to 2018 based on predefined selection criteria. Inclusion criteria involved patients with dyslipidemia, with or without PCSK-9 inhibitors, liver function tests and lipid profile at baseline and at a mean of 6-month follow-up. The variables, including age, gender, and confounding factors like other medications (statin, oral antidiabetic, and antihypertensive) induced, or chronic secondary liver diseases causing liver injury were taken into consideration. Exclusion criteria included patients without dyslipidemia. Results: The mean age of the study population was 64 ± 11 years (63% males and 37% females). The lipid profile including triglyceride and cholesterol levels during 6-month follow-up visit showed a mean of 184 ± 260 and 163 ± 50 mg/dL as compared to that at baseline of 227 ± 603 and 181 ± 70 mg/dL, respectively. In terms of clinical efficacy, a 6-month follows-up showed a drop in t...Continue Reading
References
Jan 29, 2003·Proceedings of the National Academy of Sciences of the United States of America·Nabil G SeidahMichel Chretien
Apr 3, 2012·Journal of the American College of Cardiology·James M McKenneyEvan A Stein
Jul 28, 2012·Journal of Clinical Lipidology·Peter P TóthEileen E Ming
Feb 13, 2013·The Journal of Biological Chemistry·Tanja KosenkoThomas A Lagace
Mar 15, 2014·Circulation Research·Nabil G SeidahMajambu Mbikay
May 16, 2014·JAMA : the Journal of the American Medical Association·Jennifer G RobinsonUNKNOWN LAPLACE-2 Investigators
Oct 4, 2015·Indian Heart Journal·Sanjiv Gupta
Dec 8, 2015·Atherosclerosis·Michel FarnierStephen Donahue
Jan 19, 2016·Current Opinion in Lipidology·Brian A Ference
May 28, 2016·Journal of Managed Care & Specialty Pharmacy·Marian McDonaghSergio Fazio
Aug 29, 2016·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Enrico Agabiti Rosei, Massimo Salvetti
Nov 16, 2016·JAMA : the Journal of the American Medical Association·Stephen J NichollsSteven E Nissen
Feb 6, 2017·Journal of the American College of Cardiology·Jennifer G RobinsonJohn J P Kastelein
Feb 6, 2017·Current Pharmaceutical Design·Konstantinos Tziomalos
Mar 16, 2017·World Journal of Cardiology·Rahul ChaudharyAndrew Sumner
Nov 18, 2017·Circulation·Matthew T MeffordEmily B Levitan
Jul 28, 2018·Clinical Pharmacology and Therapeutics·Muhammed T GürgözeJeanine E Roeters van Lennep
Aug 19, 2018·Clinical Cardiology·Erik StroesMichael J Koren
Dec 1, 2014·European Cardiology·Reynaria N Pitts, Robert H Eckel
Oct 16, 2018·Current Pharmaceutical Design·Eleni TheocharidouOlga Giouleme
Jul 6, 2019·The Lancet. Diabetes & Endocrinology·Kausik K RayUNKNOWN ODYSSEY OUTCOMES Committees and Investigators